Katya Galactionova

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Emergency Department

Prognostic Factors

Drug Administration

Top Venues

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Chloe Morozoff, Euripide Avokpaho, Saravanakumar Puthupalayam Kaliappan, James Simwanza, Samuel Paul Gideon, Wongani Lungu, Parfait Houngbegnon, Katya Galactionova, Maitreyi Sahu, Khumbo Kalua, Adrian J F Luty, Moudachirou Ibikounlé, Robin Bailey, Rachel Pullan, Sitara Swarna Rao Ajjampur, Judd Walson, Arianna Rubin Means
Costs of community-wide mass drug administration and school-based deworming for soil-transmitted helminths: evidence from a randomised controlled trial in Benin, India and Malawi. BMJ open 12 (7) (2022)
Katya Galactionova, Maitreyi Sahu, Samuel Paul Gideon, Saravanakumar Puthupalayam Kaliappan, Chloe Morozoff, Sitara Swarna Rao Ajjampur, Judd Walson, Arianna Rubin Means, Fabrizio Tediosi
Costing interventions in the field: preliminary cost estimates and lessons learned from an evaluation of community-wide mass drug administration for elimination of soil-transmitted helminths in the DeWorm3 trial. BMJ open 11 (7) (2021)